TECP
MIRM icon

Trails Edge Capital Partners’s Mirum Pharmaceuticals MIRM Stock Holding History

Trails Edge Capital Partners’s Portfolio MIRM Stock Details MIRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$26.1M Sell
223,312
-110,000
-33% -$11M 4.15% 9
2026
Q1 		$30.8M Buy
333,312
+301,450
+946% +$28.4M 7.05% 4
2025
Q4 		$2.52M Buy
+31,862
New +$2.29M 0.62% 23

Other funds holding MIRM

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Trails Edge Capital Partners's MIRM Position: Q2 2026 in Review

Trails Edge Capital Partners reduced its Mirum Pharmaceuticals (MIRM) stake by 33% in Q2 2026, selling an estimated $11M and leaving 223,312 shares worth $26.1M. The position accounts for 4.15% of the portfolio, ranked #9.

Trails Edge Capital Partners first reported a position in MIRM in Q4 2025 and has held it in 3 quarters since. The position peaked at $30.8M in Q1 2026. 327 funds tracked by Wall St. Rank hold MIRM as of Q2 2026.

  • Trails Edge Capital Partners held 223,312 shares of Mirum Pharmaceuticals worth $26.1M as of Q2 2026.
  • Trails Edge Capital Partners sold 110,000 Mirum Pharmaceuticals shares in Q2 2026, an estimated $11M.
  • Mirum Pharmaceuticals made up 4.15% of Trails Edge Capital Partners's portfolio in Q2 2026, its #9 holding.
  • Trails Edge Capital Partners first reported a position in Mirum Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • Trails Edge Capital Partners's Mirum Pharmaceuticals position peaked at $30.8M in Q1 2026.
  • 327 funds tracked by Wall St. Rank held Mirum Pharmaceuticals as of Q2 2026.

Based on Trails Edge Capital Partners's 13F filing for Q2 2026, filed 14 Aug 2026.